Karo Pharma AB (KARO.ST)
22 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Karo Pharma AB Q4 Adjusted EBITDA Rises To SEK 41.8 Mln
- BRIEF-Karo Pharma Says RORgamma Project Is Not Shut Down
- BRIEF-Karo Pharma Rights Issue Subscribed To 170 Percent
- BRIEF-Karo Pharma: New Issue To Provide Up To SEK 794.3 Mln Before Issue Costs
- BRIEF-Karo Pharma says sets price in guaranteed share issue at 29 SEK/share